Search research articles
Contact Us
Filters
Showing results (21-30 of 60) with videos related to
Page
of 6
Sort By:
Leukemia Research
|
January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 8, 2016
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
Marcelo C Pasquini, Jennifer Le-Rademacher, Xiaochun Zhu, et al.
Leukemia Research
|
November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
Samantha L Price, Jeffrey E Lancet, Timothy J George, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 27, 2011
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation
Janelle B Perkins, Jongphil Kim, Claudio Anasetti, et al.
International Journal of Hematology
|
January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications
Joseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
Asmita Mishra, Roni Tamari, Amy E DeZern, et al.
Leukemia Research
|
July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
Justin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Blood Advances
|
October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
Chezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 2, 2013
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting
Mohamed A Kharfan-Dabaja, Claudio Anasetti, Hugo F Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
Chezi Ganzel, Judith Manola, Dan Douer, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 60) with videos related to
Sort By:
Page
of 6
Leukemia Research
|
January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 8, 2016
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
Marcelo C Pasquini, Jennifer Le-Rademacher, Xiaochun Zhu, et al.
Leukemia Research
|
November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
Samantha L Price, Jeffrey E Lancet, Timothy J George, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 27, 2011
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation
Janelle B Perkins, Jongphil Kim, Claudio Anasetti, et al.
International Journal of Hematology
|
January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications
Joseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
Asmita Mishra, Roni Tamari, Amy E DeZern, et al.
Leukemia Research
|
July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
Justin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Blood Advances
|
October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
Chezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 2, 2013
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting
Mohamed A Kharfan-Dabaja, Claudio Anasetti, Hugo F Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
Chezi Ganzel, Judith Manola, Dan Douer, et al.
Page
of 6